Ultralife (ULBI) EBIT (2010 - 2026)

Ultralife's EBIT history runs 17 years deep, the most recent figure standing at -$215000.0 for Q1 2026.

• On a quarterly basis, EBIT fell 106.33% year-over-year to -$215000.0 in Q1 2026; TTM through Mar 2026 was -$9.5 million, a 202.31% decrease from a year earlier, with the FY2025 full-year figure at -$5.9 million, down 159.23% from the prior year.
• EBIT improved to -$215000.0 in Q1 2026 per ULBI's latest filing, from -$10.6 million in the prior quarter.
• Across five years, EBIT topped out at $4.1 million in Q1 2024 and bottomed at -$10.6 million in Q4 2025.
• The 5-year median for EBIT is $793000.0 (2022), against an average of $791294.1.
• Across the five-year window, EBIT soared 15526.92% in 2024 and tumbled 819.54% in 2025, its largest moves.
• Year by year, EBIT stood at $217000.0 in 2022, then surged by 1581.57% to $3.6 million in 2023, then plunged by 59.61% to $1.5 million in 2024, then tumbled by 819.54% to -$10.6 million in 2025, then soared by 97.97% to -$215000.0 in 2026.
• Per Business Quant, the three latest ULBI EBIT figures stand at -$215000.0 (Q1 2026), -$10.6 million (Q4 2025), and -$951000.0 (Q3 2025).